Drug Landscape ›
Ascorbic Acid 500 MG ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 32
Most-reported reactions
Alanine Aminotransferase Increased — 7 reports (21.88%) Therapy Cessation — 5 reports (15.62%) Acute Kidney Injury — 3 reports (9.38%) Incorrect Dose Administered — 3 reports (9.38%) Therapy Interrupted — 3 reports (9.38%) Transaminases Increased — 3 reports (9.38%) Aspartate Aminotransferase Increased — 2 reports (6.25%) Blood Creatinine Increased — 2 reports (6.25%) Cardiac Arrest — 2 reports (6.25%) Respiratory Failure — 2 reports (6.25%)
Source database →
Ascorbic Acid 500 MG in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ascorbic Acid 500 MG approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Ascorbic Acid 500 MG in United States?
Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.